Joshua K. Sabari, MD

Joshua K. Sabari, MD, discusses FDA approval of first-line amivantamab plus lazertinib for locally advanced or metastatic EGFR-mutated non–small cell lung cancer.

The panel discusses treatment considerations for consolidation durvalumab.

The panel discusses data necessary for selecting patients with unrespectable non–small cell lung cancer for sequential vs concurrent chemoradiotherapy.

The panel looks at a second patient case study.

The panel discusses management of resectable early-stage non–small cell lung cancer.

The panel discusses the factors that go into selecting patients for adjuvant therapy.

The panel discusses reassessing for respectability after certain treatments.

Joshua K. Sabari, MD, discusses barriers to biomarker testing in patients with non–small cell lung cancer.

A variety of treatment options in ES NSCLC are explored by key opinion leaders.

The panel discusses a variety of clinical trials and the impact on patient treatment in early stage NSCLC.

Panelists discuss the utilization of testing and multidisciplinary approaches for testing.

Medical experts discuss a specific case for a patient diagnosed with stage IIIB NSCLC.

Joshua K. Sabari, MD, discusses the FDA approval of frontline amivantamab plus chemotherapy for NSCLC harboring EGFR exon 20 insertion mutations.

Joshua K. Sabari, MD, reviews data from the 5-year overall survival update from the POSEIDON study investigating durvalumab, tremelimumab, and chemotherapy in first-line metastatic non–small cell lung cancer.

Joshua K. Sabari, MD, discusses the investigation of patritumab deruxtecan in EGFR-mutant non–small cell lung cancer.

The expert panel closes its discussion with advice for community physicians and discusses the future treatment landscape for advanced non–small cell lung cancer.

In closing, experts share future perspectives in KRAS G12C-mutated NSCLC, emphasizing novel targeted therapies and emerging trials in the evolving treatment landscape.

Shared insight on the clinical management of hepatotoxicity with use of KRAS G12C inhibitors in mNSCLC.

The panel discusses the use of antibody-drug conjugates for patients with EGFR-mutant non–small cell lung cancer, with a focus on the HERTHENA-Lung01 and TROPION-Lung05 studies.

A panel of experts on non–small cell lung cancer provide their thoughts MARIPOSA-2, which studied amivantamab and chemotherapy in EGFR-mutant NSCLC in the second line and beyond.

Experts discuss the difference in toxicities demonstrated in both adagrasib and sotorasib in second line KRAS-mutated NSCLC, highlighting hepatotoxicity and achieving durable response with combination PD-1/PD-L1 inhibitors.

Dr. Sabari and Dr. Garon discuss second line sotorasib and the results of the CodeBreaK 200 study, highlighting the recent FDA oncologic drugs advisory committee (ODAC) and their assessment of the study results.

Joshua K. Sabari, MD, reviews data from the MARIPOSA-2 trial and discusses treatment options in the second line and beyond for patients with EGFR-mutant non–small cell lung cancer.

The panel reacts to the MARIPOSA trial, which looked at amivantamab and lazertinib in the front line in patients with EGFR-mutant non–small cell lung cancer.

Comprehensive insights on FLAURA2, which looked at osimertinib and chemotherapy in the front line for patients with EGFR-mutant NSCLC.

A panel of thoracic medical oncologists discuss the first-line treatment options for patients with EGFR-mutant advanced non–small cell lung cancer.

Expert oncologists discuss patients who may progress to the second line setting with KRAS G12C mutations.

A comprehensive review of hepatotoxicity in ongoing studies evaluating KRAS inhibitors in the frontline setting, highlighting adagrasib and sotorasib in the KRYSTAL-7 and CodeBreaK 100 studies, respectively.

Joshua K. Sabari, MD, and Edward B. Garon, MD, MS, discuss the role and potential impact of KRAS G12C inhibitors in the frontline setting, highlighting the potential of monotherapy and in combination with a PD-1/PD-L1 inhibitor.

Shared insight into the consideration of KRAS G12C inhibitors in treating co-mutations in NSCLC.